Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.60
(
0.40%
)
Bitcoin
81,410.01
(
0.44%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 126552

Friday, 05/03/2013 5:41:01 PM

Friday, May 03, 2013 5:41:01 PM

Post# of 257566
TEVA/MNTA—In scanning some old posts, I came across yet another instance of misdirection by Teva’s Bill Marth (who is no longer with the company). Marth said as recently as late 2011 that Teva was still developing the “low volume” formulation of Copaxone: #msg-67094037. We know now that this program is dead, and it was probably dead even then.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today